Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Biotech & pharma
ZUG, Switzerland, Oct. 08, 2026 -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of HAE attacks in adolescents and adults have been published in The Lancet (Journal Impact Factor: 109.0).
Oct 8 · 22:35·GlobeNewswire
Healthcare · Biotech & pharma
BETHESDA, Md., Oct. 8, 2026 -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and the UK National Health Service Blood and Transplant ("NHSBT") announce that...
Oct 8 · 21:01·PR Newswire
Finance · Biotech & pharma
New York, New York--(October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact...
Oct 8 · 20:40·Newsfile
Biotech & pharma
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial
Oct 8 · 20:30·GlobeNewswire
Finance · Healthcare
PALO ALTO, Calif., October 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca’s next-generation oral selective estrogen
Oct 8 · 20:12·Business Wire
Finance · Healthcare
PALO ALTO, Calif., October 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m.
Oct 8 · 20:05·Business Wire
AI · SaaS
Springville, UT Thursday Oct 8, 2026 @ 3:00 PM Eastern —
As summer gives way to fall and daily schedules become more structured, ORGANA is encouraging consumers to use the change of seasons as an opportunity to return to simple, consistent wellness habits.
Fall often brings a shift in routines. Vacations wind down, school and work schedules settle in, temperatures cool and the busy holiday season begins to approach. For ORGANA, the transition is a reminder that wellness routines don't need to be complicated to become part of everyday life.
One area that can receive less attention as temperatures fall is hydration. While people often think about water, electrolytes and minerals during hot summer months and outdoor activities, ORGANA believes attention to hydration and minerals can be part of a year-round wellness routine.
"Fall is a great time to look at the little things you do every day and get back into a routine," said Larry Mills, CEO of ORGANA. "Our philosophy has always been to make wellness simple. You don't need to completely change your life when the seasons change. Consistency with a few everyday habits can go a long way."
That philosophy is reflected across ORGANA's product portfolio, including its Pomegranate Mineral Drink.
ORGANA Plant-Derived Trace Minerals are sourced from an ancient mineral deposit in Utah and provide a concentrated blend of naturally occurring trace minerals. The liquid format is designed to make the product easy to incorporate into an existing daily routine.
ORGANA's Pomegranate Mineral Drink combines its plant-derived mineral complex with pomegranate flavor in a ready-to-use liquid format, providing another option for consumers looking to make minerals part of their everyday routine.
The company's broader wellness portfolio also includes Liquid Oxygen 125 PPM and Essiac Tea, reflecting ORGANA's focus on straightforward products that can fit into different lifestyles and routines.
As consumers transition into fall, ORGANA recommends focusing on habits that are realistic enough to maintain throughout the season. Drinking water regularly, paying attention to hydration even when temperatures are cooler, maintaining a consistent sleep schedule, staying active and establishing simple daily routines can provide a more practical approach than trying to overhaul everything at once.
For ORGANA, the seasonal message is also a reminder that wellness isn't limited to a particular time of year. The habits that receive attention during summer can remain part of everyday routines throughout fall and into winter.
"Summer makes people naturally think about hydration," Mills said. "When the weather cools down, it's easy to stop thinking about it. We want to remind people that hydration and minerals don't have an offseason."
Consumers can explore and purchase ORGANA products through the company's Amazon storefront and on OneLavi.com. To learn more about the company's wellness philosophy visit organa.net.
About ORGANA International
Founded in 1997, ORGANA International is a wellness company committed to delivering natural, bioavailable products that help people live healthier lives. From trace minerals and liquid oxygen to magnesium creams and detoxification teas, ORGANA’s product line is designed to restore vital elements often missing in modern lifestyles. Headquartered in Springville, Utah, ORGANA is a customer-first company with a 5-star BBB rating and nearly three decades of dedication to natural wellness.
FDA Disclaimer
These statements have not been evaluated by the Food and Drug
Oct 8 · 19:00·Newsworthy.ai
Healthcare · Biotech & pharma
Partnership pairs ALCMI's international lung cancer research network with Sophos IRB's specialized oncology IRB expertise. SAN CARLOS, Calif., Oct. 8, 2026 -- The Addario Lung Cancer Medical Institute (ALCMI), an international nonprofit specializing in investigator-initiated...
Oct 8 · 18:16·PR Newswire
Finance · AI
WARREN, N.J., Oct. 08, 2026 -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”).
Oct 8 · 18:10·GlobeNewswire
Healthcare · Biotech & pharma
LOS ANGELES, Oct. 8, 2026 -- More than 5,000 ear, nose and throat specialists from around the world will gather in Los Angeles next week for the American Academy of Otolaryngology–Head and Neck Surgery's 2026 Annual Meeting & OTO EXPO. The event will feature new research on...
Oct 8 · 15:06·PR Newswire
Healthcare · Biotech & pharma
Montreal, Quebec and Vienna, Austria--(October 8, 2026) - Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to PrSIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker.Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycardia including atrial...
Oct 8 · 14:47·Newsfile
Biotech & pharma
Government-backed research into next-generation psychedelics and neuroplastogens for addictive disorders underscores the continued momentum behind this promising drug class. TAMPA, Fla., Oct. 8, 2026 -- Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering...
Oct 8 · 12:15·PR Newswire